期刊文献+

4-[4-氟-3-(哌嗪-1-羰基)苄基]-2H-酞嗪-1-酮合成工艺研究

Synthesis of 4-(4-fluoro-3-(piperazine-1-carbonyl) benzyl)phthalazin-1(2H)-one
下载PDF
导出
摘要 对PARP抑制剂4-[4-氟-3-(哌嗪-1-羰基)苄基]-2H-酞嗪-1-酮的合成工艺进行了改进,使用更为价廉的邻苯二甲酰亚胺作为起始原料,经选择性还原、加成、水解制得关键中间体2-氟-5-[(4-氧代-3,4-二氢酞嗪-1-基)甲基]苯甲酸,然后与1-叔丁氧羰基哌嗪缩合制得目标化合物,总收率达41.9%。用质谱、核磁共振氢谱确定了目标化合物的结构。与原工艺相比,该方法起始原料价廉易得,降低了成本,避免了大量的含碱废水,更易于工业化。 The synthesis of the PARP inhibitors 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2 H)-one was optimized. The key intermediate was prepared with phthalimide as the starting material. Through reduction,addition reaction and hydrolysis,2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl) methyl]benzoic acid was obtained.The target compound was synthesized by the condensation of tert-butyl piperazine-1-carboxylate with the key intermediate mentioned above. The total yield was 41. 9%. The structures of the target product and key intermediates were verified by MS and1 H NMR. Compared with the original process,the starting material of this optimal synthetic procedure was cheap,reducing the cost and avoiding a large amount of alkali-containing waste water. And it was easier to industrialize.
作者 陈升 陈绘如
出处 《广州化工》 CAS 2018年第4期31-32,50,共3页 GuangZhou Chemical Industry
关键词 PARP抑制剂 4-[4-氟-3-(哌嗪-1-羰基)苄基]-2H-酞嗪-1-酮 合成 PARP inhibitors 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one synthesis
  • 相关文献

参考文献4

二级参考文献35

  • 1RISHNAKUMAR R, KRAUS W L. The PARP side of the lucleus: Molecular actions, physiological outcomes, and :linical targets[J]. Mol Cell, 20% 0, 39{1 ):8-24.
  • 2D'AMOURS D, SALLMANN F R, DIXIT V M, eta/. Gain- of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: Implications for apoptosis[J].J Cell Sci, 2001, 114(Pt 20):3771-3778.
  • 3BRYANT H E, SCHULTZ N, THOMAS H D, et al. Specific killing of BRAC2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase[J]. Nature, 2005, 434(7035):913-917.
  • 4WlLLIAMSON C T, MUZIK H, TURHAN A G, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors[J]. Mol Cancer ?-her, 2010, 9(2):347-357.
  • 5TENTORI L, MUZI A, DORIO A S, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent[J]. Curt Cancer Drug Targets, 2010,10(4):368-383.
  • 6HORTON T M, JENKINS G, PATI D, et al. Poly(AOP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia ceils: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity[J]. Mol Cancer Ther, 2009, 8(8):2232-2242.
  • 7BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium[J]. Cancer Biol Ther, 2009, 8(1):2-3.
  • 8KUMMAR S, JIJ, MORGAN R, et al. A phase ][ study of veliparib in combination with metronomiccyclophosphamide in adults with refractory solid tumors and lymphomas[J]. C/in Cancer Res, 201 2, 18(6):1726-1734.
  • 9LOSER D A, SHIBATA A, SHIBATA A K, eta/. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair[J]. Mol Cancer Ther, 2010, 9(6):1 775-1 787.
  • 10Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant[J]. Oncology (Williston Park), 2011,25(12):1213, 1232.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部